Cerity Partners
MGX icon

Cerity Partners’s Metagenomi Therapeutics MGX Stock Holding History

Cerity Partners’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$40.8K – 2608
2024
Q2 		$40.8K Buy
+10,000
New +$68.7K ﹤0.01% 2182

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cerity Partners's MGX Position: Q3 2024 in Review

Cerity Partners sold out of Metagenomi Therapeutics (MGX) in Q3 2024, closing a stake of 10,000 shares — an estimated $40.8K sold.

Cerity Partners first reported a position in MGX in Q2 2024 and held it in 1 quarter. The position peaked at $40.8K in Q2 2024. 67 funds tracked by Wall St. Rank hold MGX as of Q3 2024.

  • Cerity Partners reported no remaining Metagenomi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cerity Partners sold 10,000 Metagenomi Therapeutics shares in Q3 2024, an estimated $40.8K.
  • Cerity Partners first reported a position in Metagenomi Therapeutics in Q2 2024 and held it in 1 quarter.
  • Cerity Partners's Metagenomi Therapeutics position peaked at $40.8K in Q2 2024.
  • 67 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2024.

Based on Cerity Partners's 13F filing for Q3 2024, filed 12 Nov 2024.